New Drug Combinations for Childhood Leukemia
Co-targeting BET Bromodomain Proteins and Aberrant Signaling in AML.
This project looks for better drug combinations to treat acute myeloid leukemia (AML) in children, adolescents, and young adults.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11138431 on NIH RePORTER |
What this research studies
Acute myeloid leukemia (AML) in children, adolescents, and young adults often has different genetic changes compared to adult AML, leading to poor cure rates. This project aims to find new ways to fight this type of leukemia by targeting two key pathways that drive its growth. Researchers will test promising drug combinations that block both abnormal gene activity and faulty cell signals. They will also work to understand why these drug combinations are effective and why some leukemia cells might become resistant, using models grown from patient samples.
Who could benefit from this research
Good fit: This research is relevant for children, adolescents, and young adults diagnosed with acute myeloid leukemia (AML).
Not a fit: Patients with other types of leukemia or cancers not related to AML would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more effective and less toxic treatments for children and young adults with acute myeloid leukemia.
How similar studies have performed: While individual targeted therapies have shown promise, this specific combination of targeting BET proteins and MEK signaling in pediatric AML, along with understanding resistance, represents a novel approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Huang, Benjamin — University of California, San Francisco
- Study coordinator: Huang, Benjamin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.